CG MedTech Co.Ltd.

As of June 30, 2026, CG MedTech Co.Ltd. carries a market capitalization of 660.86B, placing it among publicly traded companies globally. Its enterprise value stands at 670.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CG MedTech Co.Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, CG MedTech Co.Ltd. has 103.26M shares outstanding.

As of June 30, 2026, CG MedTech Co.Ltd. trades at a trailing price-to-earnings ratio of 80.18. The price-to-sales ratio is 10.26, and the price-to-book ratio stands at 6.90.

As of June 30, 2026, CG MedTech Co.Ltd. trades at an EV/EBITDA multiple of 137.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 13.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 355.33 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 670.81B versus a market cap of 660.86B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CG MedTech Co.Ltd. maintains a current ratio of 2.10, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, CG MedTech Co.Ltd. posted a return on equity (ROE) of 7.12, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 5.36, measuring how efficiently the asset base is converted into earnings. The company generates approximately 437.60M in revenue per employee across its workforce of 117.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.78 indicates how many times CG MedTech Co.Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, CG MedTech Co.Ltd. recorded an income tax benefit of -3.79B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 2.75B, leaving 6.55B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, CG MedTech Co.Ltd.'s stock has declined approximately 8.36% over the past 52 weeks. The 50-day moving average sits at 5,327.80, while the 200-day moving average is 7,839.40.

Over the twelve months ended June 30, 2026, CG MedTech Co.Ltd. generated 51.20B in revenue and converted that into 6.55B in net income, yielding earnings per share of 79.61. EBITDA reached 4.87B, while operating income came in at 1.89B.

As of June 30, 2026, CG MedTech Co.Ltd. holds 10.75B in cash and equivalents against 20.51B in total debt, resulting in a net debt position of 8.51B. Total book value stands at 95.83B, with working capital of 23.51B providing operational flexibility.

CG MedTech Co.Ltd. produced -1.91B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -21.31B in capital expenditures, free cash flow totaled -23.22B - equivalent to -282.86 per share.

Over the twelve months ended June 30, 2026, CG MedTech Co.Ltd. posted a gross margin of 41.69, reflecting its pricing power and cost economics. The operating margin of 3.69 and net profit margin of 12.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.42: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.13, meaning CG MedTech Co.Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CG MedTech Co.Ltd.'s most recent stock split took place on October 7, 2026 with a 5:1 split ratio.

As of June 30, 2026, CG MedTech Co.Ltd. has an Altman Z-Score of 10.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.